TICAGRELOR

Search structure
Trade Names:
Synonyms:
Status: Approved (2011)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: B01AC24
UNII: GLH0314RVC

Structure
InChI Key OEKWJQXRCDYSHL-FNOIDJSQSA-N
Smile CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
InChI
InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C23H28F2N6O4S
Molecular Weight 522.58
AlogP 2.01
Hydrogen Bond Acceptor 11.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 10.0
Polar Surface Area 138.44
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 36.0

Pharmacology

Action Mechanism of Action Reference
NEGATIVE ALLOSTERIC MODULATOR Purinergic receptor P2Y12 negative allosteric modulator FDA
Primary Target
P2Y12 receptor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Nucleotide-like receptor (family A GPCR) Purine receptor
- 5-5140 - 2-14 -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Coronary Disease 4 D003327 ClinicalTrials
Diabetes Mellitus, Type 2 4 D003924 ClinicalTrials
Myocardial Infarction 4 D009203 ClinicalTrials
Thrombosis 4 D013927 ClinicalTrials
Renal Insufficiency, Chronic 3 D051436 ClinicalTrials
Aortic Valve Stenosis 3 D001024 ClinicalTrials
Atrial Fibrillation 3 D001281 ClinicalTrials
Intracranial Aneurysm 3 D002532 ClinicalTrials
ST Elevation Myocardial Infarction 3 D000072657 ClinicalTrials
Non-ST Elevated Myocardial Infarction 3 D000072658 ClinicalTrials
Peripheral Arterial Disease 3 D058729 ClinicalTrials
Angina, Stable 3 D060050 ClinicalTrials
Anemia, Sickle Cell 3 D000755 ClinicalTrials
Carotid Stenosis 2 D016893 ClinicalTrials
Aortic Aneurysm, Abdominal 2 D017544 ClinicalTrials
Pulmonary Disease, Chronic Obstructive 2 D029424 ClinicalTrials
Pneumonia 2 D011014 ClinicalTrials
Ischemia 1 D007511 ClinicalTrials
Kidney Diseases 1 D007674 ClinicalTrials
Cardiovascular Diseases 1 D002318 ClinicalTrials

Side Effects from Label

Side effects Relative Frequency (%) Labels
Cardiac disorders Dyspnoea 13.8
Investigations Haemoglobin 7.9
Vascular disorders Haemorrhage 7.9
Cardiac disorders Dyspnoea 7.8
Investigations Haemoglobin 7.7
Vascular disorders Haemorrhage 7.7
Nervous system disorders Headache 6.5
Nervous system disorders Headache 5.8
Respiratory, thoracic and mediastinal disorders Cough 4.9
Cardiac disorders Atrial fibrillation 4.6
Respiratory, thoracic and mediastinal disorders Cough 4.6
Cardiac disorders Dizziness 4.5
Investigations Haemoglobin 4.5
Vascular disorders Haemorrhage 4.5
Gastrointestinal disorders Nausea 4.3
Cardiac disorders Atrial fibrillation 4.2
Vascular disorders Hypertension 4.0
Cardiac disorders Dizziness 3.9
Investigations Haemoglobin 3.8
Vascular disorders Haemorrhage 3.8
Vascular disorders Hypertension 3.8
Gastrointestinal disorders Nausea 3.8
Gastrointestinal disorders Diarrhoea 3.7
General disorders and administration site conditions Non-cardiac chest pain 3.7
Musculoskeletal and connective tissue disorders Back pain 3.6
Cardiac disorders Chest pain 3.5
Musculoskeletal and connective tissue disorders Back pain 3.3
Gastrointestinal disorders Diarrhoea 3.3
Vascular disorders Hypotension 3.3
General disorders and administration site conditions Non-cardiac chest pain 3.3
General disorders and administration site conditions Asthenia 3.2
General disorders and administration site conditions Fatigue 3.2
Vascular disorders Hypotension 3.2
Cardiac disorders Chest pain 3.1
Investigations Haemoglobin 2.8
Vascular disorders Haemorrhage 2.8
Investigations Haemoglobin 2.2
Vascular disorders Haemorrhage 2.2
Investigations Haemoglobin 0.567
Vascular disorders Haemorrhage 0.567
Investigations Haemoglobin 0.0264
Vascular disorders Haemorrhage 0.0264
Investigations Haemoglobin 0.0246
Vascular disorders Haemorrhage 0.0246

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Vascular disorders
17.07
Cardiac disorders
13.65
General disorders and administration site conditions
10.62
Respiratory, thoracic and mediastinal disorders
9.07
Injury, poisoning and procedural complications
8.11
Nervous system disorders
7.77
Gastrointestinal disorders
5.97
Skin and subcutaneous tissue disorders
4.39
Musculoskeletal and connective tissue disorders
4.23
Investigations
4.04
Psychiatric disorders
3.64

Cross References

Resources Reference
CAS NUMBER 274693-27-5
ChEBI 68558
ChEMBL CHEMBL398435
DrugBank DB08816
DrugCentral 4184
FDA SRS GLH0314RVC
Human Metabolome Database HMDB0015702
Guide to Pharmacology 1765
KEGG D09017
PDB TIQ
PharmGKB PA165374673
PubChem 9871419
SureChEMBL SCHEMBL1979652
ZINC ZINC000028957444
CONTENTS